Sutro Biopharma
STRO
49 hedge funds and large institutions have $128M invested in Sutro Biopharma in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
31% more capital invested
Capital invested by funds: $97.3M → $128M (+$30.2M)
14% more funds holding
Funds holding: 43 → 49 (+6)
0.17% more ownership
Funds ownership: 4.75% → 4.92% (+0.17%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$4.28M |
| 2 |
SCM
Sio Capital Management
New York
|
+$1.22M |
| 3 |
State Street
Boston,
Massachusetts
|
+$667K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$546K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$453K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$2.25M |
| 2 |
BlackRock
New York
|
-$978K |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$928K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$157K |
| 5 |
Morgan Stanley
New York
|
-$91.7K |
STRO Hedge Fund Activity: Q1 2019 in Review
49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2019, worth a combined $128M — up 31% from $97.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new STRO positions and 2 closed out — a net gain of 6 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was Tekla Capital Management, adding an estimated $4.28M. The largest seller was Nexthera Capital, exiting entirely with an estimated $2.25M sold.
- 49 institutional investors held Sutro Biopharma (STRO) as of Q1 2019, up from 43 in Q4 2018.
- Funds reported $128M of Sutro Biopharma stock for Q1 2019, up 31% quarter-over-quarter.
- 8 funds opened new Sutro Biopharma positions in Q1 2019 and 2 closed out, a net change of +6 holders.
- The largest Sutro Biopharma buyer in Q1 2019 was Tekla Capital Management, an estimated $4.28M added.
- The largest Sutro Biopharma seller in Q1 2019 was Nexthera Capital, an estimated $2.25M sold.
Based on aggregated 13F filings for Q1 2019.